Szela Mary T — SEC Form 4 filings

SEC reporting owner CIK 1410289. 19 Form 4 filings on record with FilingPulse; latest filed 2026-07-06.

Transaction summary — filings shown

Covers all 19 filings on record, filed 2024-02-14 to 2026-07-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
TriSalus Life Sciences, Inc. (TLSI)CEO and President, Director1110 legs · 109,566 sh · $430,0382 legs · 20,302 sh · $79,38310
Absci Corp (ABSI)Director41 leg · 12,900 sh · $148,8665
Kura Oncology, Inc. (KURA)Director33
Omega Therapeutics, Inc. (OMGA)Director11

Form 4 filings — Szela Mary T

FiledFormIssuerReported transactionsSource
2026-07-064Absci Corp (ABSI)Purchase (P): 12,900 @ $11.54EDGAR
2026-07-014TriSalus Life Sciences, Inc. (TLSI)Grant/award (A): 3,990 @ $3.87EDGAR
2026-06-154/AAbsci Corp (ABSI)Grant/award (A): 8,400 @ $0 · Grant/award (A): 33,200 (derivative) @ $0EDGAR
2026-06-084Absci Corp (ABSI)Grant/award (A): 10,100 @ $0 · Grant/award (A): 39,800 (derivative) @ $0EDGAR
2026-06-044Kura Oncology, Inc. (KURA)Grant/award (A): 35,000 (derivative) @ $0EDGAR
2026-05-184TriSalus Life Sciences, Inc. (TLSI)Purchase (P): 39,682 @ $2.59EDGAR
2026-03-204TriSalus Life Sciences, Inc. (TLSI)Sale (S): 4,358 @ $4.13 · Sale (S): 15,944 @ $3.85EDGAR
2026-02-234TriSalus Life Sciences, Inc. (TLSI)Purchase (P): 30,487 @ $4.10EDGAR
2025-11-254TriSalus Life Sciences, Inc. (TLSI)Grant/award (A): 125,000 @ $0 · Grant/award (A): 125,000 @ $0 · Grant/award (A): 300,000 @ $0 · Grant/award (A): 250,000 (derivative) @ $0EDGAR
2025-07-094Absci Corp (ABSI)Grant/award (A): 178,400 (derivative) @ $0EDGAR
2025-06-064Kura Oncology, Inc. (KURA)Grant/award (A): 28,500 (derivative) @ $0EDGAR
2025-02-194TriSalus Life Sciences, Inc. (TLSI)Grant/award (A): 21,089 @ $0EDGAR
2025-01-314TriSalus Life Sciences, Inc. (TLSI)Purchase (P): 5,030 @ $5.03 · Purchase (P): 5,010 @ $5.28EDGAR
2025-01-294TriSalus Life Sciences, Inc. (TLSI)Grant/award (A): 40,000 @ $0 · Purchase (P): 4,826 @ $5.42 · Purchase (P): 4,716 @ $5.12 · Grant/award (A): 240,000 (derivative) @ $0EDGAR
2024-09-134TriSalus Life Sciences, Inc. (TLSI)Purchase (P): 7,520 @ $5.20 · Purchase (P): 1,295 @ $4.83 · Purchase (P): 6,000 @ $5EDGAR
2024-09-124TriSalus Life Sciences, Inc. (TLSI)Purchase (P): 5,000 @ $4.97EDGAR
2024-06-214Omega Therapeutics, Inc. (OMGA)Grant/award (A): 25,000 (derivative) @ $0EDGAR
2024-06-074Kura Oncology, Inc. (KURA)Grant/award (A): 26,000 (derivative) @ $0EDGAR
2024-02-144TriSalus Life Sciences, Inc. (TLSI)Grant/award (A): 84,899 @ $0 · Grant/award (A): 288,750 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1410289 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →